Suchen
Ascendis Pharma A/S
ASNDZur Watchlist hinzufügen
261.580USD
+23.570+9.90%
Handelsschluss 06/25, 16:00（ET）Kurse um 15 Minuten verzögert
16.25BMarktkapitalisierung
37.69KGV TTM
mehr Informationen über Ascendis Pharma A/S Unternehmen
Ascendis Pharma A/S is a Denmark-based company that manufactures pharmaceutical products. The Company produces products for the treatments of growth hormone deficiency, endocrinology, central nervous system disorders, infectious diseases, and diabetes. The Company operates globally though its subsidiaries: Ascendis Pharma GmbH (Germany), Ascendis Pharma, Inc. (Delaware, United States), Ascendis Pharma Endocrinology, Inc. (Delaware, United States), Ascendis Pharma, Ophthalmology Division A/S (Denmark), Ascendis Pharma, Endocrinology Division A/S (Denmark), Ascendis Pharma Bone Diseases A/S (Denmark), Ascendis Pharma Growth Disorders A/S (Denmark) and Ascendis Pharma Oncology Division A/S (Denmark).
Ascendis Pharma A/S Informationen
BörsenkürzelASND
Name des UnternehmensAscendis Pharma A/S
IPO-datumJan 28, 2015
CEOMoller Mikkelsen (Jan)
Anzahl der mitarbeiter- -
WertpapierartDepository Receipt
GeschäftsjahresendeJan 28
AddresseTuborg Boulevard 12
StadtHELLERUP
BörseNASDAQ OMX - NASDAQ BASIC
LandDenmark
Postleitzahl2900
Telefon4570222244
Websitehttps://ascendispharma.dk/
BörsenkürzelASND
IPO-datumJan 28, 2015
CEOMoller Mikkelsen (Jan)
Führungskräfte von Ascendis Pharma A/S
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Flemming Steen Jensen
Mr. Flemming Steen Jensen
Executive Vice President, Product Supply and Quality
Executive Vice President, Product Supply and Quality
11.39K
--
Mr. Michael Wolff Jensen
Mr. Michael Wolff Jensen
Executive Vice President, Chief Legal Officer, Member of the Executive Board
Executive Vice President, Chief Legal Officer, Member of the Executive Board
5.76K
+66.49%
Mr. Lars Holtug, CPA
Mr. Lars Holtug, CPA
Independent Director
Independent Director
2.66K
+40.20%
Dr. Albert Cha, M.D., Ph.D.
Dr. Albert Cha, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
2.16K
+49.63%
Ms. Siham Imani
Ms. Siham Imani
Independent Director
Independent Director
1.10K
+66.82%
Ms. Lisa Bright
Ms. Lisa Bright
Independent Director
Independent Director
--
-100.00%
Dr. Stina Singel, M.D., Ph.D.
Dr. Stina Singel, M.D., Ph.D.
Executive Vice President, Head of Clinical Development, Oncology
Executive Vice President, Head of Clinical Development, Oncology
--
--
Mr. William Carl (Bill) Fairey, Jr.
Mr. William Carl (Bill) Fairey, Jr.
Independent Director
Independent Director
--
--
Mr. Mads Bodenhoff
Mr. Mads Bodenhoff
Senior Vice President, Head of Finance and Principal Accounting Officer
Senior Vice President, Head of Finance and Principal Accounting Officer
--
-100.00%
Dr. Aimee Shu,, M.D.
Dr. Aimee Shu,, M.D.
Executive Vice President, Chief Medical Officer
Executive Vice President, Chief Medical Officer
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Flemming Steen Jensen
Mr. Flemming Steen Jensen
Executive Vice President, Product Supply and Quality
Executive Vice President, Product Supply and Quality
11.39K
--
Mr. Michael Wolff Jensen
Mr. Michael Wolff Jensen
Executive Vice President, Chief Legal Officer, Member of the Executive Board
Executive Vice President, Chief Legal Officer, Member of the Executive Board
5.76K
+66.49%
Mr. Lars Holtug, CPA
Mr. Lars Holtug, CPA
Independent Director
Independent Director
2.66K
+40.20%
Dr. Albert Cha, M.D., Ph.D.
Dr. Albert Cha, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
2.16K
+49.63%
Ms. Siham Imani
Ms. Siham Imani
Independent Director
Independent Director
1.10K
+66.82%
Ms. Lisa Bright
Ms. Lisa Bright
Independent Director
Independent Director
--
-100.00%
Häufig gestellte Fragen
Wer sind die fünf größten Anteilseigner von Ascendis Pharma A/S?
Die fünf größten Anteilseigner von Ascendis Pharma A/S sind: Mr. Flemming Steen Jensen
Wie viele Institutionen halten Anteile an Ascendis Pharma A/S (ASND)?
Mit Stand vom 2026Q1 halten 582 Institutionen Anteile an Ascendis Pharma A/S, mit einem Gesamtmarktwert von etwa 69.20M, was 111.42% der Gesamtanteile entspricht. Im Vergleich zum 2025Q4 ist der institutionelle Aktienbesitz um -1676383.00 gestiegen.
Was ist die größte Einnahmequelle von Ascendis Pharma A/S?
Am 2026Q1 erzielte das Geschäft mit Commercial sale of products für Ascendis Pharma A/S den höchsten Umsatz in Höhe von 683.57M, was 94.92% des Gesamtumsatzes entspricht.
